银屑病患儿在接受乌司奴单抗、依那西普或甲氨蝶呤治疗前后标签扩展期的感染风险
本队列研究利用美国保险索赔数据,纳入2338例开始接受乌司奴单抗、依那西普或甲氨蝶呤治疗的银屑病患儿,比较6个月内感染发生率。调整后乌司奴单抗组门诊感染率低于依那西普组和甲氨蝶呤组,严重感染少见,标签扩展前后结果相似。
要点
- 乌司奴单抗组门诊感染调整率比为0.58(95%CI 0.41-0.83) vs 依那西普组。
- 乌司奴单抗组门诊感染调整率比为0.66(95%CI 0.48-0.91) vs 甲氨蝶呤组。
- 严重感染少见,乌司奴单抗组18.4/1000人年(3例事件)。
核心结论
- 在接受免疫调节剂治疗的银屑病患儿中,严重感染不常见。
- 本队列研究提示,与依那西普或甲氨蝶呤相比,开始乌司奴单抗治疗的患儿门诊感染风险未见增加。
研究设计与样本
- 队列研究,使用美国临床实践保险索赔数据。
- 纳入17岁及以下银屑病患儿,正在使用外用药物并开始新治疗(乌司奴单抗、依那西普或甲氨蝶呤)。
- 按儿童标签前(2009-2015年)和儿童批准后(2016-2021年)分层分析。
- 随访从开始治疗第1天起至6个月结束。
- 排除后共2338例患者(女孩1368例[57.8%]),其中乌司奴单抗379例、依那西普779例、甲氨蝶呤1180例,2009年至2021年。
主要发现
- 倾向评分调整后严重感染发生率:乌司奴单抗组18.4/1000人年(3例事件),依那西普组25.6/1000人年(9例事件),甲氨蝶呤组14.9/1000人年(8例事件)。
- 调整后门诊感染率:乌司奴单抗组254.9/1000人年(39例事件),依那西普组435.7/1000人年(139例事件),甲氨蝶呤组433.6/1000人年(209例事件)。
- 调整后门诊感染率比:乌司奴单抗 vs 依那西普为0.58(95%CI 0.41-0.83),乌司奴单抗 vs 甲氨蝶呤为0.66(95%CI 0.48-0.91),依那西普 vs 甲氨蝶呤为0.95(95%CI 0.75-1.21)。
- 标签外使用期和儿童标签后率比相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Psoriasis in children is increasingly treated with systemic medications, yet their risk of serious infection is not well characterized in clinical practice. Pediatric clinical trials for these medications were often small and placebo controlled. OBJECTIVE: To estimate the 6-month rate of infections among children with psoriasis who started treatment with ustekinumab, etanercept, or methotrexate. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used insurance claims data from clinical practices across the US on children aged 17 years or younger with psoriasis who were receiving treatment with a topical medication for psoriasis and started new treatment with ustekinumab, etanercept, or methotrexate. The analysis was stratified by the time before pediatric labeling (2009-2015) and after pediatric approval (2016-2021). Patient follow-up started 1 day after initiating treatment and ended at 6 months. EXPOSURES: New treatment with ustekinumab, etanercept, and methotrexate. MAIN OUTCOMES AND MEASURES: During follow-up, the frequency of inpatient serious infections and outpatient infections requiring treatment was compared. Event rates and rate ratios were estimated after propensity score decile stratification. RESULTS: After exclusions, we identified 2338 patients (1368 girls [57.8%]) who initiated new treatment with a targeted immunomodulating agent. In all, 379 patients started treatment with ustekinumab, 779 patients started treatment with etanercept, and 1180 patients started treatment with methotrexate from 2009 through 2021. The propensity score-adjusted incidence rate of serious infection was 18.4 per 1000 person-years (3 events) for ustekinumab users, 25.6 per 1000 person-years (9 events) for etanercept users, and 14.9 per 1000 person-years (8 events) for methotrexate users. The adjusted rate of outpatient infections was 254.9 per 1000 person-years (39 events) for ustekinumab users, 435.7 per 1000 person-years (139 events) for etanercept users, and 433.6 per 1000 person-years (209 events) for methotrexate users. The adjusted rate ratio of outpatient infections was 0.58 (95% CI, 0.41-0.83) for ustekinumab vs etanercept, 0.66 (95% CI, 0.48-0.91) for ustekinumab vs methotrexate, and 0.95 (95% CI, 0.75-1.21) for etanercept vs methotrexate. Rate ratios were similar during the off-label use era and after pediatric labeling. CONCLUSIONS AND RELEVANCE: Among children with psoriasis who started treatment with immunomodulating agents, serious infections were infrequent. This cohort study suggests that there was no increase in the risk of outpatient infections for children who started treatment with ustekinumab compared with etanercept or methotrexate.
引用
- Schneeweiss MC, Savage TJ, Wyss R, et al. Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion. JAMA Dermatol. 2023. PMID: 36753234. doi:10.1001/jamadermatol.2022.6325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。